Skymab Biotherapeutics
PrivateLast Round
Grant
Jun 2, 2026
Total Funding Raised
$690,000
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Skymab Biotherapeutics operates in Healthcare & Life Sciences and is based in Tours. Its latest recorded funding round was a Grant round in June 2026.
Skymab Biotherapeutics is a drug discovery company that designs, engineers, and develops antibody-drug conjugates (ADCs) targeting G-protein-coupled receptors (GPCRs) for applications in oncology.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Skymab Biotherapeutics Comparables
Compare Skymab Biotherapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Daiichi Sankyo | 74% | |
| AstraZeneca | 72% | |
| Confo Therapeutics | 69% |
For institutional investors. Book with your work email.
Skymab Biotherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jun 2, 2026 | ||||
| Grant | Feb 16, 2024 | ||||
| Grant | Jul 16, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Skymab Biotherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Pfizer | Grant |
| Paris-Saclay Cancer Cluster | Grant |
| Bpifrance | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 2, 2026
Received grant funding from Paris-Saclay Cancer Cluster.
- Feb 16, 2024
Received grant funding from Pfizer.
For institutional investors. Book with your work email.
Skymab Biotherapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Skymab Biotherapeutics's valuation, stock price, and market status.
Is Skymab Biotherapeutics a public or private company?
Skymab Biotherapeutics is a private company.
What is the current stock price of Skymab Biotherapeutics?
Skymab Biotherapeutics is a private company, so its shares have no public market price. Caplight tracks Skymab Biotherapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Skymab Biotherapeutics worth (valuation)?
Valuation information for Skymab Biotherapeutics is not publicly available.
Can I buy Skymab Biotherapeutics stock?
Skymab Biotherapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Skymab Biotherapeutics's last funding round?
Skymab Biotherapeutics's most recent funding round was Grant on June 2, 2026.
Who are the main investors in Skymab Biotherapeutics?
Key investors in Skymab Biotherapeutics include Pfizer, Paris-Saclay Cancer Cluster, Bpifrance.
Will Skymab Biotherapeutics IPO soon?
No public IPO plans have been announced for Skymab Biotherapeutics.
How can I track Skymab Biotherapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Skymab Biotherapeutics's shares on secondary markets.